Table 3.
Characteristics of included studies investigating body image (BI) in females with breast cancer (BCP) treated with breast-conserving therapy (BCT) and mastectomy (MX)
| Study | CO | BCP with BCT | BCP with MX | Age(mean/ range) | BI QU | Qualityof study | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | BI score mean(SD) | Tumor size/ cancer stage | Treatment | N | BI score mean(SD | Tumor size/ cancer stage | Treatment | |||||
| aJendrian et al., 2017 | GER | 46 |
6.84 (6.30) |
Tis/T1: 36 T2/T3/T4: 5 |
Surgery, Chemotherapy, Endocrine therapy | 61 |
11.51 (7.67) |
Tis/T1: 44 T2/T3/T4: 12 |
Surgery, Chemotherapy, Endocrine therapy |
68/ 36.4–83.8 |
BIS | NOS: 6 |
| bJayasinghe et al., 2021 | SL | 19 |
58.35 (55.39) |
T1: 15 T2: 27 T3 :5 T4 :2 |
Surgery, Adjuvant Chemotherapy, Hormone therapy, Adjuvant Radiotherapy, Axillary surgery |
35 |
62.51 (27.68) |
T1: 15 T2: 27 T3: 5 T4: 2 |
Surgery, Chemotherapy, Hormone therapy, Radiotherapy, Axillary surgery |
58/ 36–81 |
EORT QOL-BR 23 | ROBINS-I: MODERATE |
| bMunshi et al., 2010 | IND | 142 |
77.70 (21.80) |
Early BC: 119 Advanced BC: 23 |
Adjuvant radiotherapy, Surgery |
113 |
79.80 (35.20) |
Early BC: 51 Advanced BC: 62 |
Adjuvant radiotherapy, Surgery | na | EORT QOL-BR 23 |
ROBINS-I: LOW |
| bKing et al., 2000 | AU | 261 |
71.00 (15.00) |
T1 and T2 (no exact number)/ Early stage of BC |
Surgery, Radiotherapy, Chemotherapy |
43 |
48 (28) |
T1 and T2 (na)/ Early stage of BC |
Surgery, Radiotherapy, Chemotherapy |
BCT:54/25-81 MX:53 |
ESBC | NOS: 5 |
| bKonieczny and Fal, 2023 | PL | 125 |
58.97 (32.22) |
na. | Surgery, Radiotherapy, Chemotherapy, Hormonal therapy, Systemic therapy | 64 |
58.73 (31.16) |
na. |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy, Systemic therapy |
55/ na. |
EORT QOL-BR 23 | ROBINS-I: LOW |
| bDubashi et al.,2010 | IND | 18 |
76.88 (33.03) |
T1: 2 T2: 31 T3: 18 |
Surgery, Chemotherapy, Hormonal therapy, Bilateral salpingo-oopherectomy | 33 |
82.38 (26.20) |
T1: 2 T2: 31 T3: 18 |
Surgery, Chemotherapy, Hormonal therapy, Bilateral salpingo-oopherectomy |
30/ na. |
EORT QOL-BR 23 |
ROBINS-I: LOW |
| bMock, 1988 | USA | 90 |
97.20 (12.31) |
Early BC stage |
Surgery, Adjuvant chemotherapy |
62 |
98.20 (12.47) |
Early BC stage |
Surgery, Adjuvant chemotherapy |
52/ 29–79 |
BIS | NOS: 4 |
| bJankowska-Polańska et al., 2020 | PL | 50 |
74.50 (24.99) |
na./ na |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy | 50 |
57.39 (24.25) |
na./ na |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy |
53/ na |
EORT QOL-BR 23 |
ROBINS-I: LOW |
| aArdakani et al., 2020 | IRI | 109 |
12.87 (6.41) |
T1: 10 T2: 11 T3: 8 T4: 11 na: 140 na |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy | 71 |
15.18 (6.51) |
T1: 10 T2: 11 T3: 8 T4: 11 na: 140 na |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy |
46/ 25–70 |
BIS |
ROBINS-I: LOW |
| aFonseca et al., 2014 | PRT | 26 | 3.69 |
na./ na |
Surgery, Neoadjuvant chemotherapy |
29 |
8.24 (7.22) |
na./ na |
Surgery, Neoadjuvant chemotherapy |
54/ 32–79 |
BIS |
ROBINS-I: MODERATE |
| aAerts et al., 2014 | BE | 81 |
1.53 (3.48) |
na./ na. |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy | 68 |
6.99 (7.58) |
na./ na. |
Surgery, Radiotherapy, Chemotherapy, Hormonal therapy |
BCT: 57/ 34-75 MX: 54/ 26–74 |
BIS | NOS: 7 |
| Montañés -Muro et al., 2023 | SPA | 13 |
0.64 (0.38) |
na./ na |
Surgery | 14 |
0.91 (0.47) |
na./ na. |
Surgery |
53/ 38–70 |
BIS | NOS: 7 |
| bParker et al., 2007 | USA | 104 |
23.6 (6.90) |
na./ Stage I and II BC |
Chemotherapy, Radiotherapy, Surgery |
45 |
22.50 (5.10) |
na./ Stage I and II BC |
Chemotherapy, Radiotherapy, Surgery |
BCT : 53 MX: 52/ na |
MBSRQ | NOS: 8 |
| aShekhar et al.,2023 | IND | 402 |
2.78 (3.67) |
T1: 215 T2: 187/ 0: 10 1: 72 2: 253 3: 34 |
Hormone therapy, Radiotherapy, Surgery |
304 |
29.38 (11.55) |
T2: 148 T3: 156/ 0: 24 3: 280 |
Hormone therapy, Radiotherapy, Surgery |
< 35 : 28 35-55: 362 55-70: 266 > 70: 50 |
OBC |
ROBINS-I: LOW |
| *Spatuzzi et al.,2016 | ITA | 72 | na | BC stage 1–2 | Surgery, Chemotherapy, Radiotherapy, Hormone therapy | 44 | na | BC stage 1 & 2 |
Surgery, Chemotherapy, Radiotherapy, Hormone therapy |
BCT mean: 57 MX mean: 61.3 |
EORT QOL-BR 23 |
ROBINS-I: LOW |
| *Arican Alicikus et al., 2009 | TUR | 61 | na | na | Surgery, Chemotherapy, Radiotherapy, Hormone therapy | 51 | na | na |
Surgery, Chemotherapy, Radiotherapy, Hormone therapy |
50/ 31–65 |
MBSRQ |
ROBINS-I: LOW |
| *Yilmazer et al., 1994 | TUR | 40 | na | BC stage 1& 2 | Surgery, Chemotherapy, Radiotherapy | 40 | na | BC stage 1 and 2 |
Surgery, Chemotherapy, Radiotherapy |
BCT: 40/ 27–50 MX: 43/ 30–50 |
A draw a person test |
ROBINS-I: MODERATE |
| *Fung et al., 2001 | CHN | 17 | na |
Tis:1 T1:10 T2:6 |
Surgery | 15 | na |
Tis:1 T1: 4 T2:!0 |
Surgery |
BCT: 47 /na MX: 50 /na |
Adopted initially the body image index |
ROBINS-I: LOW |
| *Schou et al., 2005 | NOR | 85 | na |
Tis:2 T1:68 T2:30 |
Systematic therapy, Surgery, Radiotherapy |
66 | na |
Tis:2 T1:68 T2:30 |
Systematic therapy, Surgery, Radiotherapy |
56/ 21–78 |
CAWAC |
ROBINS-I: LOW |
| *Yurek et al., 2000 | USA | 78 | na |
T2: 165 T3: 25 |
Surgery, Adjuvant therapy |
79 | na |
T2: 165 T3: 25 |
Surgery, Adjuvant therapy |
51/ 30–84 |
BSS |
ROBINS-I: LOW |
| *Arikan et al., 2020 | TUR | 52 | na |
T1:9 T2: 71 T3: 19 T4: 18 |
Surgery, Chemotherapy, Target therapy, Hormone therapy |
58 | na |
T1:9 T2: 71 T3: 19 T4: 18 |
Surgery, Chemotherapy, Target therapy, Hormone therapy |
56/ 27–91 |
BIS |
ROBINS-I: LOW |
| *Afshar-Bakshloo et al.,2023 | GER | 212 | Na |
T0: 161 T1: 48 |
Surgery, Chemotherapy, Target therapy, Radiotherapy |
27 | Na | T0: 27 |
Surgery, Chemotherapy, Target therapy, Radiotherapy |
EORT QOL-BR 23 |
ROBINS-I: MODERATE |
|
| *Kraus, 1999 | USA | 16 | na | Early BC | na | 15 | na | Early BC | Surgery |
52/ 29–82 |
BIS* | NOS: 4 |
BIS body image scale (Hopwood et al. 2001), BIS*: body image scale- modified version (Polivy et al. 1977), OBC objectified body consciousness (McKinley and Hyde 1996), MBSRQ multidimensional body-self relations questionnaire (Cash 1990), EORT QoL-BR 23 european organization for research and treatment of cancer quality of life in patients with breast cancer (Sprangers et al. 1996), CAWAC caring about women and cancer (Veronesi et al. 1999), BSS body satisfaction scale (Berscheid et al. 1973), ESBC enhanced body image scale for breast cancer (Kenny et al. 2000), A draw a person test (Machover 1949), Adopted initially the body image index (Lasry et al., 1987), n.a. missing data, NOS newcastle-ottawa scale, ROBINS-I risk of bias in non-randomised studies - of interventions, BI QU body image related questionnaires, a negative direction, b positive direction, * studies in only qualitative analysis, CO country, GER Germany, NOR Norway, BE Belgium, IRI Iran, CHN China, ITA Italy, IND India, SPA Spain, PRT Portugal, PL Poland, SL Sri Lanka, TUR Turkey, AU Australia